Contact

All Stories

  1. Tuberculosis Vaccines: Multidimensional Exploration and Breakthroughs from Innovative Design to Evaluation Systems

    Article • Vaccines, November 2025, MDPI AG

    Dr. Wenping Gong

  2. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...

    Article • The Lancet, October 2025, Elsevier

    Professor Alexandru Corlateanu, Dr Muhammad Shahzad Aslam, Prof. Tomasz M. Karpiński, Xiaodong Sun, Adilson Marques, Dr Priyadarshini Bhattacharjee, Dr Emeka W. Dumbili, Dr Syed Muhammad Yousaf Farooq, Prof. Tabarak Malik, Mohammad Meshbahur Rahman, Prof. Dr Martin Siegel, Kamoru Ademola Adedokun, Dr Khurshid Ahmad, Dr Miyuru Chandradasa, Mr Ukachukwu Okoroafor Abaraogu, Dr MEHNAZ KAMAL, Asrat Agalu Abejew, Dr Mohmmad Khursheed Alam, Dr Manpreet Singh Bhatti, Kathryn H. Jacobsen, Hosam Alzahrani, Prof Dr Mohmed Isaqali Karobari, Dr. Wenping Gong, Felix Nyande, Dr. Olumuyiwa James Peter

  3. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

    Article • The Lancet, October 2025, Elsevier

    Professor Alexandru Corlateanu, Dr Syed Muhammad Yousaf Farooq, Prof. Tomasz M. Karpiński, Xiaodong Sun, Adilson Marques, Dr Priyadarshini Bhattacharjee, Dr Emeka W. Dumbili, Mohammad Meshbahur Rahman, Kamoru Ademola Adedokun, Dr Khurshid Ahmad, Dr Miyuru Chandradasa, Mr Ukachukwu Okoroafor Abaraogu, Dr MEHNAZ KAMAL, Asrat Agalu Abejew, Dr Mohmmad Khursheed Alam, Towhid Hasan, Kathryn H. Jacobsen, Hosam Alzahrani, Dr Mohammed Kuddus, Dr. Olumuyiwa James Peter, Professor Ovidiu Constantin Baltatu, Prof Dr Mohmed Isaqali Karobari, Dr. Wenping Gong, Mr Anup Bhat, Felix Nyande

  4. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

    Article • The Lancet, October 2025, Elsevier

    Dr Muhammad Shahzad Aslam, Prof. Tomasz M. Karpiński, Adilson Marques, Dr Priyadarshini Bhattacharjee, Dr Emeka W. Dumbili, Dr Syed Muhammad Yousaf Farooq, Professor KAMRAN ALI, Kamoru Ademola Adedokun, Dr Khurshid Ahmad, Dr Miyuru Chandradasa, Mr Ukachukwu Okoroafor Abaraogu, Dr MEHNAZ KAMAL, Asrat Agalu Abejew, Dr Mohmmad Khursheed Alam, Towhid Hasan, Dr Manpreet Singh Bhatti, Kathryn H. Jacobsen, Dr Mohammed Kuddus, Dr. Olumuyiwa James Peter, Professor Ovidiu Constantin Baltatu, Prof Dr Mohmed Isaqali Karobari, Dr. Wenping Gong, Felix Nyande, Dr Dawit Zemedikun

  5. CP91110P: A Computationally Designed Multi-Epitope Vaccine Candidate for Tuberculosis via TLR-2/4 Synergistic Immunomodulation

    Article • Biology, September 2025, MDPI AG

    Dr. Wenping Gong

  6. Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention

    Article • The Lancet Infectious Diseases, July 2025, Elsevier

    Dr. Wenping Gong

  7. Diagnostic dilemmas and strain diversity in the MTBVAC phase 1b–2a trial in adults

    Article • The Lancet Global Health, June 2025, Elsevier

    Dr. Wenping Gong

  8. Application value of nucleic acid MALDI-TOF MS in mycobacterial species identification and drug resistance detection in Mycobacterium tuberculosis

    Article • Microbiology Spectrum, May 2025, ASM Journals

    Dr. Wenping Gong

  9. Development and Validation of Early Alert Model for Diabetes Mellitus–Tuberculosis Comorbidity

    Article • Microorganisms, April 2025, MDPI AG

    Dr. Wenping Gong

  10. Bibliometric analysis and knowledge mapping of diabetes mellitus combined with tuberculosis research: trends from 1995 to 2023

    Article • Frontiers in Immunology, April 2025, Frontiers

    Dr. Wenping Gong

  11. Tuberculosis vaccines and therapeutic drug: challenges and future directions

    Article • Molecular Biomedicine, January 2025, Springer Science + Business Media

    Dr. Wenping Gong

  12. Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key Data

    Article • Zoonoses, January 2025, Compuscript, Ltd.

    Dr. Wenping Gong

  13. Mendelian susceptibility to mycobacterial disease: a rare genetic disorder that demands attention

    Article • Discover Immunity, December 2024, Springer Science + Business Media

    Dr. Wenping Gong

  14. Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate

    Article • Infectious Medicine, December 2024, Tsinghua University Press

    Syed Luqman Ali, Dr. Wenping Gong

  15. Machine learning model based on SERPING1, C1QB, and C1QC: A novel diagnostic approach for latent tuberculosis infection

    Article • iLABMED, November 2024, Tsinghua University Press

    Dr. Wenping Gong

  16. Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics

    Article • iLABMED, June 2024, Tsinghua University Press

    Dr. Wenping Gong

  17. WITHDRAWN: Physiological modeling and biomechanical insights of cytokine modulation in COVID-19 and pulmonary fibrosis through a multi-dimensional graph-based approach

    Article • May 2024, Cold Spring Harbor Laboratory Press

    Dr. Wenping Gong

  18. Revisiting Bacille Calmette‐Guérin revaccination strategies: timing of immunization, Mycobacterium tuberculosis and non‐tuberculous mycobacteria infections, strain potency and standardization of randomized controlled trials

    Article • Clinical and Translational Discovery, May 2024, Wiley

    Dr. Wenping Gong

  19. Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection

    Article • Molecular Biomedicine, April 2024, Springer Science + Business Media

    Dr. Wenping Gong

  20. Editorial: Immunological aspects of emerging and re-emerging zoonoses

    Article • Frontiers in Immunology, March 2024, Frontiers

    Dr. Wenping Gong

  21. Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective

    Article • Exploration, March 2024, Wiley

    Dr. Wenping Gong

  22. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control

    Article • The Lancet Infectious Diseases, March 2024, Elsevier

    Dr. Wenping Gong

  23. Application of artificial intelligence in diagnosis of pulmonary tuberculosis

    Article • Chinese Medical Journal, February 2024, Wolters Kluwer Health

    Dr. Wenping Gong

  24. Harnessing bioinformatics for the development of a promising multi-epitope vaccine against tuberculosis: The ZL9810L vaccine

    Article • Decoding Infection and Transmission, January 2024, Elsevier

    Syed Luqman Ali, Dr. Wenping Gong

  25. Development and Evaluation of a Promising Biomarker for Diagnosis of Latent and Active Tuberculosis Infection

    Article • Infectious Diseases & Immunity, January 2024, Wolters Kluwer Health

    Dr. Wenping Gong

  26. Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention

    Article • MedComm, January 2024, Wiley

    Dr. Wenping Gong

  27. Research Advances of Tuberculosis Vaccine and its Implication on COVID-19

    Article • January 2024, Frontiers

    Dr. Wenping Gong

  28. From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning

    Article • Military Medical Research, November 2023, Springer Science + Business Media

    Dr. Wenping Gong

  29. Design and development of a multi‐epitope vaccine for the prevention of latent tuberculosis infection

    Article • iLABMED, November 2023, Tsinghua University Press

    Dr. Wenping Gong

  30. A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation

    Article • Frontiers in Immunology, November 2023, Frontiers

    Dr. Wenping Gong

  31. Building a model for the differential diagnosis of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis: A case-control study based on immunological and radiological features

    Article • International Immunopharmacology, November 2023, Elsevier

    Dr. Wenping Gong

  32. Exploring BCG vaccination as a novel approach to prevent recurrent herpes labialis

    Article • EClinicalMedicine, November 2023, Elsevier

    Dr. Wenping Gong

  33. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions

    Article • iScience, October 2023, Elsevier

    Dr. Wenping Gong

  34. Spatial-temporal patterns and influencing factors for pulmonary tuberculosis transmission in China: an analysis based on 15 years of surveillance data

    Article • Environmental Science and Pollution Research, August 2023, Springer Science + Business Media

    Dr. Wenping Gong

  35. Next-Generation TB Vaccines: Progress, Challenges, and Prospects

    Article • Vaccines, July 2023, MDPI AG

    Dr. Wenping Gong

  36. LTBI-negative close contacts of tuberculosis are more likely to develop the disease: enlightenment and lessons from a cluster outbreak

    Article • Frontiers in Public Health, July 2023, Frontiers

    Dr. Wenping Gong

  37. Verapamil Regulates the Macrophage Immunity to Mycobacterium tuberculosis through NF-κB Signaling

    Article • Current Molecular Medicine, July 2023, Bentham Science Publishers

    Dr. Wenping Gong

  38. Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing

    Article • Frontiers in Cellular and Infection Microbiology, June 2023, Frontiers

    Dr. Wenping Gong

  39. Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19

    Article • Frontiers in Immunology, May 2023, Frontiers

    Dr. Wenping Gong

  40. PP19128R, a Multiepitope Vaccine Designed to Prevent Latent Tuberculosis Infection, Induced Immune Responses In Silico and In Vitro Assays

    Article • Vaccines, April 2023, MDPI AG

    Dr. Wenping Gong

  41. A Summary on Tuberculosis Vaccine Development—Where to Go?

    Article • Journal of Personalized Medicine, February 2023, MDPI AG

    Dr. Wenping Gong

  42. Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection

    Article • Frontiers in Immunology, February 2023, Frontiers

    Dr. Wenping Gong

  43. Editorial: Research advances of tuberculosis vaccine and its implication on COVID-19

    Article • Frontiers in Immunology, February 2023, Frontiers

    Dr. Wenping Gong

  44. Corrigendum: Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB

    Article • Frontiers in Immunology, February 2023, Frontiers

    Dr. Wenping Gong

  45. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis

    Article • International Immunopharmacology, February 2023, Elsevier

    Dr. Wenping Gong

  46. Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19

    Article • Frontiers in Immunology, January 2023, Frontiers

    Dr. Wenping Gong

  47. Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB

    Article • Frontiers in Immunology, January 2023, Frontiers

    Dr. Wenping Gong

  48. Immunoinformatic-Based Multi-Epitope Vaccine Design for Co-Infection of Mycobacterium tuberculosis and SARS-CoV-2

    Article • Journal of Personalized Medicine, January 2023, MDPI AG

    Dr. Wenping Gong

  49. Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19

    Article • Journal of Korean Medical Science, January 2023, XMLink

    Dr. Wenping Gong

  50. RNA-seq Analysis of the BCG Vaccine in a Humanized Mouse Model

    Article • Zoonoses, January 2023, Compuscript, Ltd.

    Dr. Wenping Gong

  51. Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT

    Article • Frontiers in Cellular and Infection Microbiology, November 2022, Frontiers

    Dr. Wenping Gong

  52. Effect of Lymphocyte Subsets on Bone Density in Senile Osteoporosis: A Retrospective Study

    Article • Journal of Immunology Research, October 2022, Wiley

    Dr. Wenping Gong

  53. CRISPR-Based Diagnostics: A Potential Tool to Address the Diagnostic Challenges of Tuberculosis

    Article • Pathogens, October 2022, MDPI AG

    Dr. Wenping Gong

  54. Prediction of Th1 and Cytotoxic T Lymphocyte Epitopes of Mycobacterium tuberculosis and Evaluation of Their Potential in the Diagnosis of Tuberculosis in a Mouse Model and in Humans

    Article • Microbiology Spectrum, August 2022, ASM Journals

    Dr. Wenping Gong

  55. Endobronchial Valve Treatment of Tuberculous Cavities in Patients with Multidrug-Resistant Pulmonary Tuberculosis: A Randomized Clinical Study

    Article • Pathogens, August 2022, MDPI AG

    Dr. Wenping Gong

  56. The Natural Effect of BCG Vaccination on COVID-19: The Debate Continues

    Article • Frontiers in Immunology, July 2022, Frontiers

    Dr. Wenping Gong

  57. BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents

    Article • International Immunopharmacology, July 2022, Elsevier

    Dr. Wenping Gong

  58. In silico Analysis of Peptide-Based Biomarkers for the Diagnosis and Prevention of Latent Tuberculosis Infection

    Article • Frontiers in Microbiology, June 2022, Frontiers

    Dr. Wenping Gong

  59. Child hepatitis of unknown origin may be due to insufficient understanding of adenovirus pathogenicity

    Article • Hepatology Communications, June 2022, Wolters Kluwer Health

    Dr. Wenping Gong

  60. Cellular Immunity of Patients with Tuberculosis Combined with Diabetes

    Article • Journal of Immunology Research, June 2022, Wiley

    Dr. Wenping Gong

  61. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies

    Article • International Reviews of Immunology, May 2022, Taylor & Francis

    Dr. Wenping Gong

  62. The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19

    Article • Frontiers in Bioscience-Landmark, May 2022, IMR Press

    Dr. Wenping Gong

  63. Impact of Diabetes Mellitus on the Immunity of Tuberculosis Patients: A Retrospective, Cross-Sectional Study

    Article • Risk Management and Healthcare Policy, April 2022, Taylor & Francis

    Dr. Wenping Gong

  64. Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis

    Article • Therapeutics and Clinical Risk Management, March 2022, Taylor & Francis

    Dr. Wenping Gong

  65. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

    Article • BioMed Research International, February 2022, Hindawi Publishing Corporation

    Dr. Wenping Gong

  66. Peptide-Based Vaccines for Tuberculosis

    Article • Frontiers in Immunology, January 2022, Frontiers

    Dr. Wenping Gong

  67. The Research Progress in Immunotherapy of Tuberculosis

    Article • Frontiers in Cellular and Infection Microbiology, November 2021, Frontiers

    Dr. Wenping Gong

  68. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

    Article • Frontiers in Microbiology, October 2021, Frontiers

    Dr. Wenping Gong

  69. A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice

    Article • Indian Journal of Tuberculosis, August 2021, Elsevier

    Dr. Wenping Gong

  70. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?

    Article • Indian Journal of Tuberculosis, July 2021, Elsevier

    Dr. Wenping Gong

  71. Experience and Lessons of Tuberculosis Prevention and Control During COVID-19 Pandemic in Clinic

    Article • Annals of Public Health Reports, June 2021, sPage.direcT

    Dr. Wenping Gong

  72. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials

    Article • Expert Review of Vaccines, June 2021, Taylor & Francis

    Dr. Wenping Gong

  73. Comparative study on the antituberculous effect and mechanism of the traditional Chinese medicines NiuBeiXiaoHe extract and JieHeWan

    Article • Military Medical Research, June 2021, Springer Science + Business Media

    Dr. Wenping Gong

  74. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic

    Article • International Reviews of Immunology, May 2021, Taylor & Francis

    Dr. Wenping Gong

  75. Prediction and analyses of HLA‐II restricted Mycobacterium tuberculosis CD4 + T cell epitopes in the Chinese population

    Article • Biotechnology and Applied Biochemistry, May 2021, Wiley

    Dr. Wenping Gong

  76. Peptides-Based Vaccine MP3RT Induced Protective Immunity Against Mycobacterium Tuberculosis Infection in a Humanized Mouse Model

    Article • Frontiers in Immunology, April 2021, Frontiers

    Dr. Wenping Gong

  77. Exploratory development of PCR-fluorescent probes in rapid detection of mutations associated with extensively drug-resistant tuberculosis

    Article • European Journal of Clinical Microbiology & Infectious Diseases, April 2021, Springer Science + Business Media

    Dr. Wenping Gong

  78. Chinese Traditional Medicine NiuBeiXiaoHe (NBXH) Extracts Have the Function of Antituberculosis and Immune Recovery in BALB/c Mice

    Article • Journal of Immunology Research, January 2021, Hindawi Publishing Corporation

    Dr. Wenping Gong

  79. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?

    Article • Journal of Korean Medical Science, January 2021, Korean Academy of Medical Sciences (KAMJE)

    Dr. Wenping Gong

  80. Dynamic Changes in Chest CT Images Over 167 Days in 11 Patients with COVID-19: A Case Series and Literature Review

    Article • Zoonoses, January 2021, Compuscript, Ltd.

    Dr. Wenping Gong

  81. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes

    Article • Military Medical Research, June 2020, Springer Science + Business Media

    Dr. Wenping Gong

  82. Mannose-binding lectin 2 gene polymorphisms and their association with tuberculosis in a Chinese population

    Article • Infectious Diseases of Poverty, April 2020, Springer Science + Business Media

    Dr. Wenping Gong

  83. Macrophages enhance mesenchymal stem cell osteogenesis via down-regulation of reactive oxygen species

    Article • Journal of Dentistry, March 2020, Elsevier

    Dr. Wenping Gong

  84. Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

    Article • BioMed Research International, January 2020, Hindawi Publishing Corporation

    Dr. Wenping Gong

  85. Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium Tuberculosis Reactivation Mouse Model

    Article • Human Gene Therapy Methods, April 2019, Mary Ann Liebert Inc

    Dr. Wenping Gong

  86. The current status, challenges, and future developments of new tuberculosis vaccines

    Article • Human Vaccines & Immunotherapeutics, March 2018, Taylor & Francis

    Dr. Wenping Gong

  87. Th1 epitope peptides induce protective immunity against Rickettsia rickettsii infection in C3H/HeN mice

    Article • Vaccine, December 2017, Elsevier

    Dr. Wenping Gong

  88. An alert of Mycobacterium tuberculosis infection of rhesus macaques in a wild zoo in China

    Article • EXPERIMENTAL ANIMALS, January 2017, Japanese Association for Laboratory Animal Science

    Dr. Wenping Gong

  89. Enhanced Expression of T-Cell Immunoglobulin and Mucin Domain Protein 3 in Endothelial Cells Facilitates Intracellular Killing ofRickettsia heilongjiangensis

    Article • The Journal of Infectious Diseases, September 2015, Oxford University Press (OUP)

    Dr. Wenping Gong

  90. Chloroform-Methanol Residue of Coxiella burnetii Markedly Potentiated the Specific Immunoprotection Elicited by a Recombinant Protein Fragment rOmpB-4 Derived from Outer Membrane Protein B of Rickettsia rickettsii in C3H/HeN Mice

    Article • PLOS One, April 2015, PLOS

    Dr. Wenping Gong

  91. Rickettsia rickettsiiouter membrane protein YbgF induces protective immunity in C3H/HeN mice

    Article • Human Vaccines & Immunotherapeutics, February 2015, Taylor & Francis

    Dr. Wenping Gong

  92. Enhanced protection against Rickettsia rickettsii infection in C3H/HeN mice by immunization with a combination of a recombinant adhesin rAdr2 and a protein fragment rOmpB-4 derived from outer membrane protein B

    Article • Vaccine, February 2015, Elsevier

    Dr. Wenping Gong

  93. Serological characterization of surface-exposed proteins of Coxiella burnetii

    Article • Microbiology, December 2014, Society for General Microbiology

    Dr. Wenping Gong

  94. Protective immunity against Rickettsia heilongjiangensis in a C3H/HeN mouse model mediated by outer membrane protein B-pulsed dendritic cells

    Article • Science in China Series C Life Sciences, September 2014, Springer Science + Business Media

    Dr. Wenping Gong

  95. Genomic and comparative genomic analyses of Rickettsia heilongjiangensis provide insight into its evolution and pathogenesis

    Article • Infection Genetics and Evolution, August 2014, Elsevier

    Dr. Wenping Gong

  96. Identification of Novel Surface-Exposed Proteins of Rickettsia rickettsii by Affinity Purification and Proteomics

    Article • PLOS One, June 2014, PLOS

    Dr. Wenping Gong

  97. Microarray of surface-exposed proteins of rickettsia heilongjiangensisfor serodiagnosis of Far-eastern spotted fever

    Article • BMC Infectious Diseases, June 2014, Springer Science + Business Media

    Dr. Wenping Gong

  98. Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice

    Article • Vaccine, April 2014, Elsevier

    Dr. Wenping Gong, xiaolu xiong

  99. Exploratory Study on Th1 Epitope-Induced Protective Immunity against Coxiella burnetii Infection

    Article • PLOS One, January 2014, PLOS

    Dr. Wenping Gong

  100. Recombinant protein YbgF induces protective immunity against Rickettsia heilongjiangensis infection in C3H/HeN mice

    Article • Vaccine, November 2013, Elsevier

    Dr. Wenping Gong

  101. Proteome Analysis and Serological Characterization of Surface-Exposed Proteins of Rickettsia heilongjiangensis

    Article • PLOS One, July 2013, PLOS

    Dr. Wenping Gong